Fact based stock research
Verona Pharma (NMQ:VRNA)

US9250501064

How to read the free ranks

For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. The higher the rank, the better the stock performs than its peers. And, we do this for six investment strategies:
Value - shows how good of a value the stock is. Green is "inexpensive"; red is "expensive".

Growth - shows a company's growth potential. Green is "high growth" expected; red is "tough times ahead".

Safety - relates to the amount of debt a company has. Green is low debt level; red is high debt level.

Combined Financial - this isn't an average of the first three ranks but rather a consolidated view across several financial indicators. Green = good; red = tread carefully.

(NEW) Sentiment - quantifies professional analyst ratings and holdings as well as market pulse. Green = positive sentiment; red = skepticism (Only available to Premium Subscribers).

(NEW) 360° View - the ultimate rating with all financial and non-financial indicators.

Verona Pharma stock research in summary

veronapharma.com


ANALYSIS: With an Obermatt Combined Rank of 20 (worse than 80% compared with investment alternatives), Verona Pharma (Pharmaceuticals, United Kingdom) shares have lower financial characteristics compared with similar stocks. Shares of Verona Pharma are low in value (priced high) with a consolidated Value Rank of 8 (worse than 92% of alternatives), and are riskily financed (Safety Rank of 17, which means above-average debt burdens) but show above-average growth (Growth Rank of 89). ...read more


RECOMMENDATION: A Combined Rank of 20, is a sell recommendation based on Verona Pharma's financial characteristics. As the company Verona Pharma shows low value with an Obermatt Value Rank of 8 (92% of comparable investments are less expensive), investors should look at the other ranks. In this case, growth is expected to be above-average, better than 89% of comparable companies (Obermatt Growth Rank is 89). This is a typical case. Companies with above average growth tend to cost more than stocks with slower growth expectations. If this is a high-growth company, the low Obermatt Safety Rank of 17 is a good sign. The more debt a well-performing company has, the higher the returns to shareholders. However, if growth turns negative or interest rates increase, high debt may become a burden. If you believe the future is bright for Verona Pharma, even a low-value company (in terms of its key financial indicators) can be a good investment. Obermatt Premium subscribers can further check the stock’s Sentiment Ranks, which also flow into the Obermatt 360° View for investors. ...read more


Latest Obermatt Ranks


Log in or sign up to see the new 360° View and Sentiment ranks.

360° Viewnew
Sentiment Ranknew
Value Rank 8
Growth Rank 89
Safety Rank 17
Combined Rank 20
Country United Kingdom
Industry Pharmaceuticals
Index
Size class X-Small

27-Feb-2025. Stock data may be delayed. Log in or sign up to get the most recent research.


Further information

About the company

Recent company news

Add to Watchlist
See Similar Stocks
Subscribe to updates


Multiple opinions. One number.

Analysts rarely agree on a stock’s future. So, who do you believe? Obermatt translates those collective views into a single Sentiment Rank. That plus the financial ranks give you the ultimate 360° View. Sign up to access them.
Why popular stocks have low ratings

It’s easier said than done. When your stock drops, it’s easy to want to sell it and find a better performer. Think twice, or even three times, before trading. Those fees (especially the hidden ones) can eat up your gains.

Review the performance ranks of the individual metrics that form each investment strategy.

Research History: Verona Pharma

RESEARCH HISTORY 2022 2023 2024 2025
VALUE
VALUE n/a
n/a
12
8
GROWTH
GROWTH n/a
n/a
88
89
SAFETY
SAFETY n/a
n/a
17
17
SENTIMENT
SENTIMENT n/a
n/a
44
new
360° VIEW
360° VIEW n/a
n/a
35
new

Most recent update of the stock research: 27-Feb-2025. Financial reporting date used for calculating ranks: 30-Sep-2024. Stock research history is based on the Obermatt Method. The higher the rank, the better Verona Pharma is in the corresponding investment strategy.
Upgrade to a Premium Account to access the latest ranks.


Combined financial peformance in Detail

ANALYSIS: With an Obermatt Combined Rank of 20 (worse than 80% compared with investment alternatives), Verona Pharma (Pharmaceuticals, United Kingdom) shares have lower financial characteristics compared with similar stocks. Shares of Verona Pharma are low in value (priced high) with a consolidated Value Rank of 8 (worse than 92% of alternatives), and are riskily financed (Safety Rank of 17, which means above-average debt burdens) but show above-average growth (Growth Rank of 89). ...read more

RECOMMENDATION: A Combined Rank of 20, is a sell recommendation based on Verona Pharma's financial characteristics. As the company Verona Pharma shows low value with an Obermatt Value Rank of 8 (92% of comparable investments are less expensive), investors should look at the other ranks. In this case, growth is expected to be above-average, better than 89% of comparable companies (Obermatt Growth Rank is 89). This is a typical case. Companies with above average growth tend to cost more than stocks with slower growth expectations. If this is a high-growth company, the low Obermatt Safety Rank of 17 is a good sign. The more debt a well-performing company has, the higher the returns to shareholders. However, if growth turns negative or interest rates increase, high debt may become a burden. If you believe the future is bright for Verona Pharma, even a low-value company (in terms of its key financial indicators) can be a good investment. Obermatt Premium subscribers can further check the stock’s Sentiment Ranks, which also flow into the Obermatt 360° View for investors. ...read more

RESEARCH HISTORY 2022 2023 2024 2025
VALUE
VALUE n/a
n/a
12
8
GROWTH
GROWTH n/a
n/a
88
89
SAFETY
SAFETY n/a
n/a
17
17
COMBINED
COMBINED n/a
n/a
20
20

Last update of combined financial performance: 27-Feb-2025. Stock analysis on combined financial performance: The higher the rank of Verona Pharma the better the performance.


Value Metrics in Detail

ANALYSIS: With an Obermatt Value Rank of 8 (worse than 92% compared with alternatives), Verona Pharma shares are significantly more expensive than comparable stocks.

RECOMMENDATION: The overall picture with a consolidated Value Rank of 8, is a sell recommendation based on Verona Pharma's stock price compared with the company's operational size and dividend yields.


VALUE METRICS 2022 2023 2024 2025
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S) n/a
n/a
37
34
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E) n/a
n/a
n/a
n/a
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book) n/a
n/a
1
1
DIVIDEND YIELD
DIVIDEND YIELD n/a
n/a
1
1
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE n/a
n/a
12
8

Last update of Value Rank: 27-Feb-2025. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Verona Pharma; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

ANALYSIS: With an Obermatt Growth Rank of 89 (better than 89% compared with alternatives) for 2025, Verona Pharma shows one of the highest growth dynamics in its industry. Investors also speak of high momentum. The Growth Rank is based on consolidating four value indicators, with all but one indicator above average for Verona Pharma. Sales Growth has a rank of 100 which means that currently, professionals expect the company to grow more than 100% of its competitors. Capital Growth is also above 1% of competitors with a rank of 100, and Stock Returns with the rank of 100 is also an outperformance. Only Profit Growth is low with a rank of 1 which means that currently, professionals expect the company to grow its profits less than 99% of its competitors. ...read more

RECOMMENDATION: The overall picture with a consolidated Growth Rank of 89, is a buy recommendation for growth and momentum investors. All three operating growth indicators, namely revenue, profit, and capital growth, are showing improvements. This is a good indication of a company with a positive future. That might, at the same time, be the simple reason why profit growth is low. A growing company needs money and thus can't yet show high profit growth. Look out for signs in corporate communication about extra growth efforts costing time and money. If that is the case, Verona Pharma is a good growth stock. While momentum is a popular investment factor, the value aspect might be the more important one, in the longer term. We recommend analyzing the stock with Obermatt’s Value, Safety, and Sentiment Ranks to arrive at a 360° View of the stock purchase case. ...read more

GROWTH METRICS 2022 2023 2024 2025
REVENUE GROWTH
REVENUE GROWTH n/a
n/a
100
100
PROFIT GROWTH
PROFIT GROWTH n/a
n/a
1
1
CAPITAL GROWTH
CAPITAL GROWTH n/a
n/a
100
100
STOCK RETURNS
STOCK RETURNS n/a
n/a
100
100
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH n/a
n/a
88
89

Last update of Growth Rank: 27-Feb-2025. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Verona Pharma.


Safety Metrics in Detail

ANALYSIS: With an Obermatt Safety Rank of 17 (better than 17% compared with alternatives), the company Verona Pharma has much riskier financing practices than comparable other companies, which means that their overall debt burden is significantly above the industry average. This doesn't mean that the business of Verona Pharma is also risky, it only means that the company is on the riskier side in respect to bankruptcy in case things turn sour, assuming that public reporting is correct. The Safety Rank is based on consolidating three financing indicators, with just one indicator above average for Verona Pharma and the other two below average. Leverage is at a rank of 73 meaning the company has a below-average debt-to-equity ratio. It has less debt than 73% of its competitors.Refinancing is at a rank of 20, which means that the portion of the debt about to be refinanced is above-average. It has more debt in the refinancing stage than 80% of its competitors. Liquidity is at a rank of 1, meaning that the company generates less profit to service its debt than 99% of its competitors. ...read more

RECOMMENDATION: With a consolidated Safety Rank of 17 (worse than 83% compared with alternatives), Verona Pharma has a financing structure that is significantly riskier than that of its competitors. This is an indication that the company is on the riskier side when it comes to debt service. There is only below-market average liquidity, and a short-term refinancing issue might be around the corner. But in the long-term, the debt levels of Verona Pharma are on the safer side. Investors may have a short-term debt challenge and liquidity issues with Verona Pharma and should also compare Obermatt’s Value, Growth, and Sentiment Ranks before making a decision. ...read more

SAFETY METRICS 2022 2023 2024 2025
LEVERAGE
LEVERAGE n/a
n/a
71
73
REFINANCING
REFINANCING n/a
n/a
20
20
LIQUIDITY
LIQUIDITY n/a
n/a
1
1
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY n/a
n/a
17
17

Last update of Safety Rank: 27-Feb-2025. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Verona Pharma and the more cash is available to service its debt.


Sentiment Metrics in Detail

SENTIMENT 2022 2023 2024 2025
ANALYST OPINIONS
ANALYST OPINIONS n/a
n/a
80
new
OPINIONS CHANGE
OPINIONS CHANGE n/a
n/a
65
new
PRO HOLDINGS
PRO HOLDINGS n/a
n/a
n/a
new
MARKET PULSE
MARKET PULSE n/a
n/a
11
new
CONSOLIDATED RANK: SENTIMENT
CONSOLIDATED RANK: SENTIMENT n/a
n/a
44
new

Last update of Sentiment Rank: 27-Feb-2025. Stock analysis on sentiment metrics: The higher the rank, the more positive the sentiment for Verona Pharma.
Upgrade to a Premium Account to access the latest ranks.


Add to Watchlist
See Similar Stocks
Subscribe to updates

Free stock analysis by the purely fact based Obermatt Method for Verona Pharma from February 27, 2025.

Obermatt Portfolio Performance
We’re so convinced about our free research, that we buy our stock tips.
See the performance of the Obermatt portfolio.